|
WO2021069542A1
|
|
Zafirlukast derivatives for use as contraceptive agents
|
|
WO2021009237A1
|
|
A urokinase plasminogen activator receptor-targeting peptide
|
|
WO2020239687A1
|
|
18f-labeled novel tetrazines imaging probes for pretargeting in pet imaging
|
|
WO2020201276A1
|
|
A system and a method for measuring volumetric flow in arteries
|
|
WO2020165405A1
|
|
Stem cell therapy for patients with salivary gland dysfunction
|
|
WO2020165404A1
|
|
Stem cell therapy for lacrimal gland dysfunction
|
|
WO2020048918A1
|
|
A device for dispensing medication
|
|
EP3813889A1
|
|
Polypept(o)id-based graft copolymers for in vivo imaging by tetrazine transcyclooctene click chemistry
|
|
EP3774788A1
|
|
1-step radiosynthesis of [18f]sfb
|
|
JP2019077712A
|
|
177-Lu LABELED PEPTIDE FOR SITE-SPECIFIC uPAR-TARGETING
|
|
CN111479594A
|
|
68Ga-and64Cu-NODAGA-E[c(RGDyK)]2PET tracers for use in human angiogenesis imaging
|
|
WO2019048423A1
|
|
L-serine supplementation in subjects with pre-diabetes
|
|
WO2018091058A1
|
|
177-lu labeled active site inhibited factor vii
|
|
EP3381929A1
|
|
Targeted microbubbles for detection of glycocalyx
|
|
CN108883197A
|
|
Target the antibody-drug conjugates of uPARAP
|
|
WO2017129197A1
|
|
Biological sample collecting device
|
|
EP3402537A1
|
|
Quantitative pet imaging of tissue factor expression using 18f-labelled active site inhibited factor vii
|
|
WO2017080562A1
|
|
Device for reducing magnetic susceptibility artifact
|
|
AU2016342387A1
|
|
Stem cell therapy based on adipose-derived stem cells
|
|
WO2016155745A1
|
|
Cross-reactive anti-pad antibodies
|
